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Abstract
Since the last two decades, a major paradigm shift occurred in our understand-
ing of the physiological and pathophysiological roles of the mineralocorticoid 
receptor (MR). Expression of the MR in cells/tissues not involved in sodium/
potassium balance and extracellular volume homeostasis, i.e., the primary role 
of the aldosterone/MR complex, paved the way to the discovery of unsuspected 
implications of MR in a variety of cellular processes and pathological consequences. 
It also opens the possibility for quick translation to the bedside using available MR 
antagonists (MRAs) such as spironolactone, canrenone, or eplerenone or using the 
more recently developed various nonsteroidal MRAs that are not yet marketed. 
Landmark clinical trials like RALES, EPHESUS, or EMPHASIS well established 
that MRAs provide great benefits in patients with heart failure and spironolactone 
or eplerenone have been recommended in these patients. The deep understanding 
provided by preclinical studies in various domains stimulated the possibility to 
extend the use of MRAs to new fields, including renal diseases even if MRAs are 
currently contraindicated or used with great caution in patients with renal function 
impairment due to the higher risk of hyperkalemia associated with MRA therapy 
in this at-risk population. The present review presents preclinical data supporting 
potential indications in renal diseases.
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1.  Pathophysiological basis: MR activation in the kidney—where and 
what are the consequences?
1.1 MR expression in the kidney
Besides the well-known expression of MR in the so-called aldosterone-
sensitive distal nephron (ASDN) encompassing DCT1-2, CNT, and CDD, MR is 
also expressed in a variety of other cell types within the kidney [1–5]. In basal 
condition, MR is expressed in the vasculature in both endothelium [6] and 
smooth muscle cells [1]. MR expression has also been reported in the mesangium 
[7], podocytes [8], fibroblasts [9], and immune cells (macrophages, dendritic 
cells, T lymphocytes) [10–13]. In Figure 1, we summarize the effects reported for 
MR antagonists in different target cells within the kidney that represent potential 
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beneficial mechanisms acting against kidney disease progression, and that will be 
detailed below. It is important to mention that MR expression might be upregu-
lated in some pathological conditions such as diabetes [14], heavy proteinuria 
[15], vascular aging [16], and hypertension [17], leading to potential increased 
MR signaling. The specific physiological role of MR in the cells where its expres-
sion has been reported remains to be elucidated; however, it was recently pro-
posed that MR in endothelial, smooth muscle, and inflammatory cells may be an 
evolutionary mechanism to prevent hemorrhage by promoting vasoconstriction 
and thrombosis and to promote wound healing by the activation of inflammation 
and vascular remodeling [18].
1.2 MR activation: what is the ligand?
The classical ligand of the MR is aldosterone, but glucocorticoids can bind 
with similar affinity with that of MR. Of note ligand-receptor dissociation is 
faster for glucocorticoid than aldosterone, resulting in higher transactivation 
potency for aldosterone as compared to glucocorticoids, especially at low con-
centration. However, a selectivity mechanism allows aldosterone to preferentially 
activate the MR in the presence of glucocorticoids, despite much higher local 
concentration of glucocorticoids than aldosterone. The 11β-hydroxysteroid dehy-
drogenase type 2 (11β-HSD2) converts corticosterone/cortisol to compounds with 
low affinity for the MR [19]. The cellular aldosterone/glucocorticoid selectivity 
therefore depends on the expression level/activity of the HSD2. In the kidney, 
cells from the ASDN and endothelium express HSD2, while this is debated for the 
smooth muscle cells [20]. In podocytes, mesangial cells, and immune cells, for 
example, HSD2 is not expressed, therefore supporting the fact that glucocorti-
coids may be the main ligands of MR in these cells. It should be stressed, however, 
that there may be species differences as well as induction of HSD2 expression in 
some pathological conditions, allowing aldosterone to activate MR. This has not 
been carefully analyzed yet [1].
Figure 1. 
MR antagonists display beneficial effects against kidney diseases by acting in several cell types and by different 
mechanisms.
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1.3 Major pathophysiological mechanisms involved in MR and kidney diseases
1.3.1 MR and renal hemodynamic alterations
Experimental evidence in rodent models of acute kidney injury (AKI) supports 
the concept that MR contributes to vascular tone regulation [1]. The benefit of MRA 
in renal ischemia-reperfusion injury is associated with improved renal hemody-
namics and decreased renal vascular resistance [21, 22]. We recently showed that 
MR expressed in mouse smooth muscle cells contributes to renal injury induced 
by ischemia (through a mechanism involving oxidative stress and Rac1 activation) 
[23], as well as in acute CsA nephrotoxicity (due to increased vascular L-type 
calcium channel activity thereby resulting in decreased renal artery vasoconstric-
tion and overall improvement in renal hemodynamics) [24]. Of note, the endothe-
lial MR was not directly involved since endothelial MR gene inactivation had no 
effect in ischemia-reperfusion or CsA-induced renal injuries [23, 24]. Whether MR 
expressed in the renal vasculature contributes to renal injury in other settings like 
diabetes or chronic kidney diseases remains to be explored.
1.3.2 MR and oxidative stress
Multiple in vitro and in vivo studies have shown the significance of oxidative 
stress induced by aldosterone/MR and its detrimental consequences on kidney 
injury. In vivo, the DOCA-salt causes oxidative DNA damage [25], and aldosterone 
infusion produces an MR-dependent increase in NADPH oxidase activity and ROS 
generation in the kidney [26, 27]. MR expressed in the smooth muscle cell may 
have a major role as we recently demonstrated in ischemia-reperfusion injury using 
smooth muscle MR KO mice [23]. In vascular cells, aldosterone increased ROS 
which in turn modifies the cysteinyl thiols in the eNOS-activating region of endo-
thelin-1 B receptor to decrease endothelin-1-stimulated eNOS activity, impairing 
the vasodilatory pathway. These effects have repercussions on renal hemodynamics 
and function in kidney ischemia/reperfusion injury in both rat and mouse [21–23]. 
In rat mesangial cells, aldosterone directly stimulates superoxide anion generation, 
which is accompanied by an increase in NADPH oxidase activity and translocation 
of p47phox and p67phox to the cell membrane [28]. Moreover, recent studies have 
shown that aldosterone induces mesangial cell apoptosis and that the administra-
tion of an antioxidant or MR antagonist attenuates the proapoptotic effects of 
aldosterone [29]. The increase in NADPH oxidase Nox2 plasma levels and urinary 
isoprostanes is also observed in patients with primary aldosteronism as compared to 
essential hypertensive patients [30]. Interestingly, adrenalectomy is associated with 
a reduction in both parameters [30]. Moreover, therapeutic MR antagonism reduced 
oxidative stress in diabetic [31] or kidney transplant patients [32].
1.3.3 MR and inflammation
A role for MR signaling in inflammation has been suggested since early studies 
showing that the treatment of rats with aldosterone and salt causes perivascular 
leukocyte infiltration and increased expression of inflammatory markers [1]. 
More recently, macrophages, dendritic cells, and T lymphocytes have been identi-
fied as MR-expressing cells [1, 11, 33]. The use of genetically modified mouse 
model deficient of MR in myeloid cells revealed that myeloid MR contributes to 
renal injury in a glomerulonephritis mouse model [8]. Moreover, our recent work 
showed that myeloid MR participates to CKD progression induced by AKI [34]. 
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The deletion of MR in myeloid cells favored M2 polarization of renal macrophages 
leading to improved tissue repair and prevention of renal scaring, decreased 
function, and interstitial fibrosis. Interestingly MRA administration using the 
nonsteroidal MRA finerenone has similar effects, blunting CKD development after 
ischemia-reperfusion injury in rodents [22, 34] and in the large white pig [34]. The 
role of myeloid MR in the progression of CKD in other models of kidney disease has 
to be further studied. The role of MR expressed in T cell has not been explored in 
kidney disease. However, T-cell MR knockout mice prevented cardiac hypertrophy, 
fibrosis, and dysfunction compared with littermate control mice after abdominal 
aortic constriction suggesting that MR in T cells may also play a pro-inflammatory 
role [13]. In dendritic cells, MR stimulation with aldosterone induces the secretion 
of IL-6 and TGF-β, two pro-inflammatory cytokines able to polarize the adaptive 
immune response toward a Th17 phenotype [35]. MR antagonism with spironolac-
tone reduced heart and kidney damage in a hypertension rat model due to blockade 
of Th17 polarization and the induction of regulatory T cells [36]. Pharmacological 
MR blockade improves the chronic inflammatory state associated with CV disease 
[1, 33]. Altogether, these data suggest that aldosterone/MR modulates innate and 
adaptive immunity, which may have a critical role in end-organ damage.
1.3.4 MR and fibrosis
Fibrosis and extracellular matrix remodeling is a well-documented effect of 
MR activation in various tissues, including the kidney [1]. Aldosterone induces 
pro-fibrotic cytokine production and accumulation of collagen and other extra-
cellular matrix components [9, 37, 38]. Aldosterone administration is associated 
with an increase in renal TGF-β, collagen, and connective tissue growth factor 
expression and medullary and cortical fibrosis [39]. Aldosterone also influences 
the production of plasminogen activator inhibitor-1 leading to glomerulosclerosis 
[40]. MR activation in renal fibroblasts results in rapid activation of growth factor 
receptors and induction of PI3K/MAPK signaling, which stimulates proliferation 
and therefore contributes to fibrosis expansion [41]. Several molecular MR targets 
may be involved in the pro-fibrotic response of Aldo/MR signaling. We recently 
deeply explored the role of neutrophil gelatinase-associated lipocalin (NGAL) that 
we identified as a novel aldosterone/MR target [42]. NGAL induction by the MR 
might be a mechanism for MR-induced fibrosis since mice deficient in NGAL are 
protected from aldosterone-induced kidney fibrosis (Jaisser, unpublished data). 
Galectin-3 also mediates the pro-fibrotic effects of aldosterone-MR, and galectin-3 
KO mice are protected against aldosterone-induced kidney fibrosis [43]. Taken 
together increased MR activation which may promote kidney fibrosis by inducing 
fibroblast proliferation and the production of several pro-fibrotic molecules.
2.  Preclinical data supporting the benefit of MR antagonists (MRA) in 
kidney diseases
2.1  Benefit of MRA on acute kidney injury (AKI) induced by ischemia/
reperfusion (IR)
A reduction of renal blood flow is occurring in several clinical settings, and this 
is a major cause of AKI. A number of studies in rodents and in the Large White Pig 
preclinical model have shown that MR antagonism with steroidal and nonsteroidal 
MRAs prevents and treats AKI induced by IR. In an early study, it was shown that 
spironolactone is a useful strategy to prevent the acute kidney dysfunction and 
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tubular injury induced by bilateral renal IR injury in the rat [44]. The sustained 
reduction in renal blood flow observed after 24 hours in the IR-untreated rats 
was prevented in the spironolactone-treated groups. This was reproduced using 
nonsteroidal MRAs in both rats and mice [21–23] leading to the discovery of a novel 
underlying mechanism related to the limitation of oxidative stress and impaired 
endothelin-B receptor signaling [21, 22]. Importantly MRA also have curative 
effects when administered within the first 3 hours post ischemia-reperfusion [21, 
45, 46]. The benefit of MR antagonists in ischemic AKI was translated into the 
Large White Pig preclinical model in which MR antagonism with soludactone 
(potassium canrenoate, a soluble MRA used in clinics) prevented the effects of AKI 
including kidney dysfunction and structural injuries [23].
2.2 AKI to CKD transition
In recent years, special focus has been given to the chronic consequences of 
an AKI episode. Several clinical and experimental studies have shown that AKI is 
linked with increased risk for CKD development.
In the rat, CKD progression induced by a single event of ischemic AKI (charac-
terized by proteinuria, kidney dysfunction, and severe structural injury including 
interstitial fibrosis, glomerulosclerosis, tubule dilation, and podocyte injury) is 
prevented by spironolactone [45] and finerenone [22, 47]. MR antagonism also 
prevents CKD induced by a mild ischemic period even when administered 3 hours 
after the ischemia episode [48]. The underlying mechanisms rely on the limitation 
of inflammatory events and the promotion of repair mechanisms held by M2-type 
macrophages and interleukin-4 receptor signaling [34]. Importantly, these benefits 
are also observed in the Large White Pig model: short-term soludactone administra-
tion before/after the ischemic event indeed prevents CKD progression at 3 months, 
with a reduction in fibrosis and proteinuria and improved renal function [34]. The 
data indicate that MRA treatment is an encouraging therapeutic option to prevent 
the AKI to CKD transition which identifies the MR expressed in inflammatory cells 
as a specific target in this setting.
2.3 MR antagonism in kidney fibrosis and CKD progression
Kidney fibrosis is a common endpoint of CKD from different origins. 
Accumulating evidences indicate that aldosterone and/or MR signaling plays a 
key role in CKD development in a number of animal models including nephron 
reduction [49, 50], hypertensive models [51, 52], unilateral ureteral obstruction 
[53, 54], and mineralocorticoid/salt models [55]. MR antagonism not only prevents 
glomerulosclerosis in the remnant kidney model but also induces regression of 
glomerulosclerosis as evidenced by Aldigier et al. on kidney biopsy 4 weeks after 
spironolactone treatment initiation in rats already presenting CKD [56]. Eplerenone 
also limited proteinuria in this model [50]. Renal injury observed in the Dahl-
sensitive rat upon salt loading is greatly limited by eplerenone [57, 58] and the 
nonsteroidal MRA CS-3150 [59]. This may be related to a direct effect on podocyte, 
as underlined by Shibata et al., involving activation of Rac1 and possible increased 
Rac1-mediated transactivation of the podocyte MR [60].
2.4 Benefit of MR blockade in diabetic nephropathy
The beneficial effects of MRA in different models of type I and type II diabetic 
nephropathy or kidney injury related to metabolic disorders have been reported. 
Spironolactone administration for 3 weeks reduced renal collagen deposition in 
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STZ-induced diabetic rats [61]. This was thereafter reported for other MRAs such 
as eplerenone [62]. MRAs are also efficient in limiting progression of diabetic 
nephropathy in models of type 2 diabetes. Eplerenone reduced albuminuria, glo-
merular hypertrophy, and mesangial expansion in the db/db mouse model [62]. The 
novel nonsteroidal MRA AZ9977 has similar effects [63]. In the Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats or Zucker obese rats, similar benefits have been 
reported after MRA treatment [64, 65].
2.5 Calcineurin inhibitor toxicity and kidney transplantation
Some studies showed a benefit of MR blockade in acute and chronic CsA 
nephrotoxicity, including effects on preventing structural and functional 
alterations [66–68]. The underlying mechanisms leading to this protection rely 
on hemodynamic effects (blunting the sustained vasoconstriction induced by 
CNI) [24, 68] or renal extracellular matrix remodeling [67]. The effect of MRA 
in experimental kidney transplantation has been tested in a model of chronic 
allograft dysfunction in the Dark-Agouti to Wistar-Furth rat with a reduced vas-
culopathy and glomerular macrophage influx and a trend to reduced proteinuria 
and glomerulosclerosis [69].
2.6 Glomerulonephritis and MR blockade
Although few studies have addressed this issue, it has been reported that spi-
ronolactone and the nonsteroidal MRA BR-4628 are beneficial in mouse models 
of glomerulonephritis [70–72]. The myeloid MR seems to play a key role in the 
kidney since genetic deletion of MR in myeloid cells, but not in podocyte, blunted 
glomerulonephritis development [8].
3. Conclusion
Preclinical evidences clearly support the concept of a benefit of MR antagonism 
to treat or delay kidney diseases from different origins including ischemic kidney 
disease, diabetic and hypertensive nephropathy, glomerulonephritis, and calcineurin 
inhibitor toxicity in the context of kidney transplant. The underlying mechanisms 
rely on improving local hemodynamics and reducing extracellular matrix remodeling 
and local inflammation (Figure 1). Whether this translates in clinics is already largely 
supported by several clinical trials, but definitive answers should be provided by well-
designed, large clinical trials based on hard renal outcomes like limitation of CKD pro-
gression and/or cardiovascular outcomes. A recent study showed that in patients with 
heart failure with preserved ejection fraction, spironolactone treatment decreased the 
relative risk for cardiovascular death, heart failure hospitalization, or aborted cardiac 
arrest, despite an increase in the hyperkalemia risk [73]. Novel therapeutics limiting 
the risk of hyperkalemia upon MRA use is also warranted in these at-risk populations.
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